However, in patients without diabetes, the primary treatment objective is weight management
A separate study (Copinschi et al., Neuroendocrinology, 1997, N=8) demonstrated that MK-677 increased Stage IV (deep) sleep duration by 50% and REM sleep by 20%, improvements that were sustained throughout the 2-week study period
Self-sourcing and self-dosing without medical supervision is strongly discouraged, particularly for autoimmune patients who are often on complex medication regimens
Ongoing treatment depends on: Continued clinical benefit Safety and tolerability Remaining within eligibility criteria defined by the PGD GLP-1 medicines are not intended to be lifelong by default , and all patients are reviewed regularly
Alginate antacids or proton pump inhibitors (PPIs) may be appropriate for persistent symptoms, but should be discussed with your trial team or a clinician before use